Canaccord lowered the firm’s price target on Nevro to $8 from $11 and keeps a Hold rating on the shares. The firm said they reported a Q2 miss and reduced its FY24 outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO: